Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M245Revenue $M12.5Net Margin (%)-227.4Z-Score-4.3
Enterprise Value $M172EPS $-0.5Operating Margin %-208.3F-Score2
P/E(ttm))0Cash Flow Per Share $-0.6Pre-tax Margin (%)-225.8Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio2.8Cash flow > EarningsY
Price/Sales18.45-y EBITDA Growth Rate %-22.5Current Ratio2.8Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-27.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M59.4ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with THLD

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
THLDJean-Marie Eveillard 2014-03-31 Add0.01%$4.34 - $5.72
($4.92)
$ 4.12-16%Add 250%700,000
THLDJean-Marie Eveillard 2012-12-31 Buy $3.98 - $6.55
($4.67)
$ 4.12-12%New holding, 200000 sh.200,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

THLD is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
THLD Jean-Marie Eveillard 2014-03-31700,0001.180.01+250%
Premium Most recent portfolio changes are included for Premium Members only!


THLD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Dyckerhoff Stefan A10% Owner 2014-06-20Sell13,988$4.012.74view
Pullara Samuel J III10% Owner 2014-06-20Sell13,988$4.012.74view
COXE TENCH10% Owner 2014-06-20Sell13,988$4.012.74view
BIRD JEFFREY WDirector, 10% Owner 2014-06-20Sell13,988$4.012.74view
BAKER G LEONARD JR10% Owner 2014-06-20Sell13,988$4.012.74view
ANDERSON DAVID L10% Owner 2014-06-20Sell13,988$4.012.74view
YOUNGER WILLIAM H JR10% Owner 2014-06-20Sell13,988$4.012.74view
WHITE JAMES N10% Owner 2014-06-20Sell13,988$4.012.74view
SWEET DAVID E10% Owner 2014-06-20Sell13,988$4.012.74view
SUTTER HILL ENTREPRENEURS FUND10% Owner 2014-06-20Sell10,028$4.012.74view

Press Releases about THLD :

    Quarterly/Annual Reports about THLD:

    News about THLD:

    Articles On GuruFocus.com
    Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 47,619 Shares Mar 15 2011 
    Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 
    Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
    Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
    Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
    Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 52,356 Shares Oct 06 2009 
    Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2009 
    Threshold Pharmaceuticals Inc. (THLD) CEO Harold E Selick buys 20,000 Shares Jun 05 2009 
    Threshold Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2009 

    More From Other Websites
    3 Health Care Stocks Primed For Big Moves Jul 14 2014
    Threshold Announces Initiation of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD")... Jul 09 2014
    Threshold Pharmaceuticals initiates dosing with TBorD in Phase 1/2 trial Jul 09 2014
    Threshold Announces Initiation Of Dosing With TH-302/Bortezomib In Final Stage Of Ongoing Phase 1/2... Jul 09 2014
    Threshold Announces Initiation of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD")... Jul 09 2014
    Threshold Initiates Phase 2 Clinical Trial In Advanced Non-Squamous Non-Small Cell Lung Cancer Jul 08 2014
    Threshold Pharmaceuticals Initiates 440-Patient, Randomized, Double-Blind, Placebo-Controlled Trial... Jul 01 2014
    Threshold Pharmaceuticals Initiates 440-Patient, Randomized, Double-Blind, Placebo-Controlled Trial... Jul 01 2014
    THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 02 2014
    Threshold (THLD): Update from ASCO Presentation Jun 02 2014
    3 Beaten-Down Biotech Stocks That Could Double May 30 2014
    Threshold (THLD): Unleash the Power of Anti-Hypoxia for Cancer Treatment May 30 2014
    Threshold Pharmaceuticals Announces Presentation and Webcast at the Jefferies Global Healthcare... May 30 2014
    Threshold Announces Data From Ongoing Phase 1/2 Trial of TH-302 Plus Dexamethasone in Patients With... May 30 2014
    Threshold Announces Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bevacizumab (Avastin(R)) in... May 30 2014
    Threshold Announces Webcast of Analyst Event on Sunday, June 1, 2014 May 27 2014
    THRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... May 21 2014
    Threshold Announces Clinical Data on TH-302 in Glioblastoma and Relapsed/Refractory Multiple Myeloma... May 14 2014
    Threshold Pharmaceuticals Announces Presentation and Webcast at the UBS Global Healthcare Conference May 13 2014
    THRESHOLD PHARMACEUTICALS INC Financials May 09 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide